Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
Conditions
Prostate CancerSummary
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, oncologic outcomes and urinary/sexual function, and identify predictors of complications, oncological control and functional outcomes after Hhigh-intensity focused ultrasound (HIFU) ablation of prostate cancer with the intent to guide further research and improve patient care. We will include subjects who will have a HIFU procedure performed from all Sub-Investigators included in the study.
Locations
2 locations Found with status Recruiting
Status
- RECRUITING
Central Contacts
- Majlinda Tafa, MD
- (646) 825-6338
- [email protected]
Principal Investigator
- James Wysock, MD
Status
- RECRUITING
Central Contacts
- Majlinda Tafa, MD
- (646) 825-6338
- [email protected]
Principal Investigator
- James Wysock, MD
Eligibility Criteria
Inclusion Criteria:
* Males, ages 40-95
* Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy
* Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) that select focal HIFU prostate ablation as their treatment option will be offered inclusion into this prospective data collection research database.
* Patients who have early (Gleason 6 or 7), low grade cancer that is confined to the prostate.
* Willing and able to provide consent.
Exclusion Criteria:
* Patients that are not diagnosed with prostate cancer.
* Patients that are diagnosed with clinically localized prostate cancer, but select other tratment options as their desired treatment.
* Patients that are not willing or are not able to give consent.
Study Plan
Prostate Cancer Patients Scheduled for HIFU Procedure
Participants will be actively followed up for the first 3 years. After that once a year for life, unless they withdraw from the study or no longer seek standard of care at NYU Langone Health.
Outcome Measures
Primary Outcome Measures
Change in Prostate-Specific Antigen (PSA) Levels
Change in Urinary Function Score
Change in Urinary Continence Score
Change in Sexual Function Score
Change in Ejaculatory Function Score
Change in Sexual Health Inventory for Men (SHIM) Score
Decision Regret Score
Number of Participants with Persistence or Recurrence of Cancer within the Treatment Zone on Post-Treatment Imaging
Number of Participants with New Lesions in the Non-Treated Prostate on Post-Treatment Imaging
Number of Participants with Persistence or Recurrence of Cancer within the Treatment Zone on Post-Treatment Prostate Biopsy
Number of Participants with New Lesions in the Non-Treated Prostate on Post-Treatment Prostate Biopsy
Timeline
Last Updated
October 2, 2025Start Date
October 2, 2025Today
March 14, 2026Completion Date ( Estimated )
December 31, 2050
Sponsors of this trial
Lead Sponsor
NYU Langone Health